TREATMENT CENTER DIRECTORY

Natalie*
Person with PH1

*Alnylam is proud to feature real patients in our advertising. Patients may or may not be on an Alnylam therapy.

Find a treatment center

Search the Treatment Center Directory for OXLUMO® (lumasiran) to locate healthcare centers close to your patients that can administer OXLUMO.

Treatment Centers for OXLUMO are added on an ongoing basis and may not be in this locator tool yet. For additional treatment centers, please contact Alnylam Assist®.

INTERESTED IN BEING LISTED IN THE TREATMENT CENTER DIRECTORY FOR OXLUMO?

Register Now

Remove your center from this directory or update your contact information

The Treatment Center Directory for OXLUMO is an informational resource for locating a site of care administering OXLUMO. No fees or other remuneration have been or will be exchanged for a treatment center’s inclusion in this database. Inclusion of centers in this database is based on opt-in approval by authorized personnel for those sites listed. Alnylam Pharmaceuticals is not affiliated with, and inclusion in this database does not represent an endorsement of, recommendation for, or referral to, the treatment centers listed in this database. Likewise, participating centers do not endorse any Alnylam products and may not be currently administering any Alnylam products.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common (≥20%) adverse reaction reported in patients treated with OXLUMO was injection site reaction. Injection site reactions included erythema, swelling, pain, hematoma, pruritus, and discoloration.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.